TWST Twist Bioscience Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1581280 · Fiscal year ends 09/30
Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.0%
TTM net income YoY-67.6%
TTM EPS YoY-60.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—
Margins
Gross margin52.4%
Operating margin-30.4%
Net margin-28.3%
FCF margin-19.4%
EBITDA margin-24.7%
Returns
ROE-19.1%
ROA-14.8%
ROIC (approx.)-34.2%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets20.8%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue10.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q4*2026-09-30 | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $126.64M | $118.38M | $110.72M | $103.70M | $99.01M | $96.06M | $92.79M | $88.71M |
| Cost of revenue | $59.39M | $55.92M | $53.59M | $49.73M | $48.17M | $44.76M | $46.77M | $45.87M |
| Gross profit | $67.25M | $62.45M | $57.12M | $53.97M | $50.84M | $51.30M | $46.03M | $42.84M |
| R&D expense | $16.99M | $18.02M | $19.70M | $17.13M | $17.01M | $18.05M | $23.92M | $21.31M |
| SG&A expense | $74.68M | $80.71M | $76.08M | $69.74M | $63.76M | $63.37M | $63.67M | $56.18M |
| Operating income | -$24.41M | -$36.28M | -$45.86M | -$32.90M | -$29.93M | -$30.12M | -$41.56M | -$34.64M |
| Interest expense | — | — | — | — | — | — | $143,000 | $24,000 |
| Pretax income | -$20.82M | -$34.74M | -$43.98M | -$30.25M | -$26.88M | $20.58M | -$39.15M | -$31.50M |
| Income tax | -$201,000 | $311,000 | $43,000 | $253,000 | $257,000 | $191,000 | $175,000 | $97,000 |
| Net income | -$20.62M | -$35.05M | -$44.02M | -$30.51M | -$27.14M | $20.39M | -$39.33M | -$31.59M |
| EBITDA | -$17.32M | -$29.78M | -$39.76M | -$26.71M | -$23.93M | -$24.32M | -$35.46M | -$28.26M |
| EPS (basic) | — | -0.56 | -0.71 | -0.50 | — | 0.34 | -0.66 | -0.53 |
| EPS (diluted) | — | -0.56 | -0.71 | -0.50 | — | 0.33 | -0.66 | -0.53 |
| Weighted avg. shares (diluted) | — | 62.40M | 61.70M | 61.08M | — | 61.16M | 59.65M | 59.16M |
| Balance sheet | ||||||||
| Cash & equivalents | $533.99M | $117.44M | $122.67M | $148.59M | $183.05M | $203.91M | $212.95M | $224.06M |
| Short-term investments | $47.91M | $49.40M | $49.00M | $49.36M | $49.38M | $49.42M | $46.71M | $49.42M |
| Receivables | $70.19M | $65.06M | $64.15M | $50.06M | $57.02M | $49.85M | $49.95M | $39.31M |
| Inventory | $46.41M | $35.16M | $33.52M | $32.92M | $28.31M | $25.94M | $20.86M | $23.52M |
| Current assets | $737.22M | $321.30M | $323.44M | $303.88M | $332.97M | $339.78M | $338.44M | $345.31M |
| PP&E, net | $122.32M | $111.89M | $111.23M | $105.12M | $102.28M | $95.35M | $97.14M | $100.67M |
| Goodwill | $82.19M | $82.19M | $82.19M | $82.19M | $82.19M | $82.19M | $85.81M | $85.81M |
| Intangibles | $34.16M | $12.73M | $13.00M | $13.16M | $13.43M | $13.69M | $13.95M | $14.21M |
| Total assets | $1.12B | $672.44M | $676.21M | $638.09M | $641.86M | $643.61M | $595.62M | $608.58M |
| Current liabilities | $125.81M | $120.25M | $119.98M | $80.44M | $91.41M | $87.07M | $74.98M | $69.65M |
| Total liabilities | $233.79M | $226.70M | $221.12M | $181.99M | $168.90M | $165.41M | $155.51M | $152.64M |
| Shareholders' equity | $888.02M | $445.74M | $455.09M | $456.10M | $472.96M | $478.20M | $440.11M | $455.94M |
| Shares outstanding | 67.81M | 62.67M | 62.15M | 61.27M | 60.63M | 60.17M | 59.86M | 59.58M |
| Cash flow statement | ||||||||
| Operating cash flow | -$173,000 | $1.11M | -$17.56M | -$24.81M | -$11.81M | -$1.40M | -$12.99M | -$21.43M |
| Capital expenditure | $19.96M | $9.76M | $7.89M | $9.97M | $12.43M | $9.16M | $4.14M | $2.27M |
| Free cash flow | -$20.13M | -$8.65M | -$25.45M | -$34.79M | -$24.24M | -$10.56M | -$17.13M | -$23.70M |
| Investing cash flow | -$20.25M | -$10.20M | -$12.71M | -$9.93M | -$12.40M | -$9.40M | -$1.43M | -$1.54M |
| Financing cash flow | $438.45M | $3.79M | $4.14M | $298,000 | $5.57M | $1.83M | $3.20M | $17.94M |
| Depreciation & amortization | $7.10M | $6.50M | $6.10M | $6.19M | $6.00M | $5.80M | $6.10M | $6.38M |
| Stock-based compensation | $19.47M | $18.18M | $18.94M | $13.27M | $16.08M | $16.06M | $20.33M | $11.99M |
Free plan shows the latest 8 periods; Pro shows all 36 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.